| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04237584 Details | 2022-10-07 Interventional | 3 | 23 | Radium Ra 223 d… Prostatic Neopl… Metastatic Cast… | The study was stopped due to insurmountable enrollment challenges affecting trial accrual,
resulting from the rapidly evolving treatment options for advanced prostate cancer. ESCALATE (PC18-1005) was terminated early due to enrollment challenges. | |||
| NCT03827044 Details | 2022-10-07 Interventional | 3 | 30 | Avelumab Colonic Neoplas… Microsatellite … POLE Exonucleas… Stage III Colon… | POLEM encountered significant recruitment challenges. With little prospect of recruiting to
target the decision to close was made. - | |||
| NCT03764137 Details | 2022-10-07 Interventional | 1/2 | 0 | Panitumumab Colorectal Neop… Metastatic Colo… | Study was not able to enroll any subjects - | |||
| NCT03649464 Details | 2022-10-07 Interventional | 1/2 | 0 | Antineoplastic … Astrocytoma Glioblastoma Glioma Oligodendroglio… | Planned to execute the new Oral OKN-007 clinical trial with modified study plan soon. This
Study not proceeding and sites never opened. - | |||
| NCT04705051 2020-004400-34 Details | 2022-10-06 Interventional | 3 | 24 | Venglustat Kidney Diseases Kidney Diseases… Polycystic Kidn… Polycystic Kidn… Congenital Cyst… | LTS15823 (long-term extension of the EFC15392 study) was stopped after protocol specified
interim analysis for futility of the parent EFC15392 study met the prespecified stopping rule
based on the primary outcome measure. The study was terminated prematurely by the Sponsor following a decision to terminate the parent study EFC15392. Termination decision was due to lack of efficacy in ADPKD population and not linked to safety findings with venglustat. | |||
| NCT01727336 Details | 2022-10-06 Interventional | 2 | 160 | Axitinib Carcinoma Carcinoma, Rena… Advanced Renal … | The study was terminated by the sponsor following unblinding of the Progression Free Survival
endpoint. All 131 patients in Part 2 discontinued from the study; the most frequent reasons were (i) study terminated at the discretion of the sponsor [86 patients (65.6%)] and (ii) death [36 patients (27.5%)]. The discontinuations prior to planned sample collections, as outlined in the protocol schedule of events, precluded the ability to carry out all planned analyses, including but not limited to PK analyses. Dalantercept PK in patients with advanced cancer has been reported previously. | |||
| NCT04210310 Details | 2022-10-05 Interventional | 3 | 33 | Oxytocin Tinnitus | PI departure from the institution. Study was prematurely terminated due to PI/Study Team departure from institution. No outcome measure data collected or analyzed. All participants lost to follow-up. | |||
| NCT04676126 Details | 2022-10-04 Interventional | 4 | 0 | Dorzolamide Glaucoma Glaucoma, Open-… Glaucoma Eye | IRB records show administrative closure on 12/16/21. No subjects enrolled. - | |||
| NCT04604678 Details | 2022-10-04 Interventional | 2 | 0 | Metformin Naltrexone COVID-19 Covid19 | Unable to recruit participants due to restrictive inclusion/exclusion criteria. Will update
protocol with IRB & begin anew after approval. - | |||
| NCT03250299 Details | 2022-10-03 Interventional | 1 | 26 | Lisavanbulin Glioblastoma MGMT-Unmethylat… | Due to the National Cancer Institute's (NCI)-mandated termination of the Adult Brain Tumor
Consortium which was conducting the study - | |||
| NCT01665274 Details | 2022-10-03 Interventional | 2 | 15 | Capecitabine Oxaliplatin Stomach Neoplas… Gastric Cancer | we are working on a larger similar multicenter cinical trials as a participant.so in order to
avoid conflicts of interest, we have to suspended this project. - | |||
| NCT01174199 Details | 2022-10-03 Interventional | 1 | 13 | MTOR Inhibitors Sirolimus Temsirolimus Vorinostat Prostatic Neopl… Adenocarcinoma … Hormone-resista… Prostate Cancer Recurrent Prost… Stage IV Prosta… | no value in finding efficacy - | |||
| NCT04952519 2021-000981-13 Details | 2022-09-30 Interventional | 3 | 193 | Amantadine COVID-19 Patients With M… | The annual analysis did not show the efficacy of the investigational medicinal product in this
application, therefore the study was not continued. - | |||
| NCT04635683 Details | 2022-09-30 Interventional | 1 | 0 | Lenalidomide Lymphoma Lymphoma, B-Cel… Lymphoma, B-Cel… Lymphoma, Folli… Lymphoma, Mantl… Lymphoma, Non-H… Recurrence Waldenstrom Mac… Recurrent B-Cel… Recurrent Extra… Recurrent Folli… Recurrent Grade… Recurrent Grade… Recurrent Grade… Recurrent Lymph… Recurrent Mantl… Recurrent Margi… Recurrent Nodal… Recurrent Splen… Recurrent Walde… Refractory B-Ce… Refractory Extr… Refractory Foll… Refractory Grad… Refractory Grad… Refractory Grad… Refractory Lymp… Refractory Mant… Refractory Marg… Refractory Noda… Refractory Sple… Refractory Wald… | Investigational Drug removed from the market - | |||
| NCT04244058 Details | 2022-09-30 Interventional | 1 | - | Amantadine Brain Injuries Brain Injuries,… Consciousness D… Disorder of Con… Traumatic Brain… | Given CoVid-19 pandemic we could not recruit subjects/patients for the 1st year. Currently
waiting for new sponsor to fulfill the aims. - | |||
| NCT03769467 Details | 2022-09-30 Interventional | 1/2 | 12 | Pembrolizumab Carcinoma Epstein-Barr Vi… Nasopharyngeal … Nasopharyngeal … Neoplasms Viremia Virus Diseases Epstein-Barr Vi… Epstein-Barr Vi… | Phase 1B part was completed with review of DLTs and cumulative safety data by Safety Data
Review Committee and identification of a safe RP2D. Post-internal review, sponsor decided to
terminate the study, and hence, Phase 2 part was not conducted. - | |||
| NCT03399838 Details | 2022-09-30 Interventional | 4 | 0 | Dexmedetomidine Midazolam Emergencies Procedural Anxi… | Sponsor left the hospital - | |||
| NCT04132388 Details | 2022-09-29 Interventional | 4 | 0 | Adalimumab Hidradenitis Hidradenitis Su… | Sponsor and site agreed the research would not happen now; several delays and other issues - | |||
| NCT00634166 Details | 2022-09-29 Interventional | 4 | 220 | Amphotericin B Anti-Bacterial … Anti-Infective … Antifungal Agen… Bacitracin Clotrimazole Mafenide Miconazole Burns | FDA request as study could not serve as the confirmatory trial. The study was terminated on 17 June 2013 due to the recommendation and request by the FDA to design a superiority clinical study to satisfy the sponsor's post marketing study commitment for SS5%. | |||
| NCT03524898 Details | 2022-09-28 Interventional | 1/2 | 39 | Gemcitabine Paclitaxel Sarcoma Soft Tissue Sar… | As Last patient last visit (LPLV) took place on 15/02/2022, the trial was ended prematurely on
this date in accordance with SAKK/CI. - |